Autoimmune hemolytic anemia - progress in emerging treatment options

References

• Petz LD, Garratty G. Immune hemolytic anemias. 2nd ed. Philadelphia: Churchill Livingstone; 2004.
   Google Scholar
• Barcellini W, Fattizzo B, Zaninoni A, et al. Clinical heterogeneity and predictors of outcome in primary autoimmune hemolytic anemia: a GIMEMA study of 308 patients. Blood. 2014 Nov 6;124(19):2930–2936.
   PubMed Web of Science ®Google Scholar
• Barcellini W, Fattizzo B. Clinical applications of hemolytic markers in the differential diagnosis and management of hemolytic anemia. Dis Markers. 2015;2015:635670.
   PubMed Web of Science ®Google Scholar
• Fattizzo B, Zaninoni A, Nesa F, et al. Lessons from very severe, refractory, and fatal primary autoimmune hemolytic anemias. Am J Hematol. 2015 Aug;90(8):E149–51.
   PubMed Web of Science ®Google Scholar
• Barcellini W. Current treatment strategies in autoimmune hemolytic disorders. Expert Rev Hematol. 2015;8(5):681–691.
   PubMed Web of Science ®Google Scholar
• Berentsen S, Ulvestad E, Gjertsen BT, et al. Rituximab for primary chronic cold agglutinin disease: a prospective study of 37 courses of therapy in 27 patients. Blood. 2004;103:2925–2928.
   PubMed Web of Science ®Google Scholar
• Barcellini W, Zaja F, Zaninoni A, et al. Low-dose rituximab in adult patients with idiopathic autoimmune hemolytic anemia: clinical efficacy and biological studies. Blood. 2012;119:3691–3697.
   PubMed Web of Science ®Google Scholar
• Birgens H, Frederiksen H, Hasselbalch HC, et al. A phase III randomized trial comparing glucocorticoid monotherapy versus glucocorticoid and rituximab in patients with autoimmune haemolytic anaemia. Br J Haematol. 2013;163:393–399.
   PubMed Web of Science ®Google Scholar
• Berentsen S, Randen U, Vågan AM, et al. High response rate and durable remissions following fludarabine and rituximab combination therapy for chronic cold agglutinin disease. Blood. 2010;116:3180–3184.
   PubMed Web of Science ®Google Scholar
• Berentsen S, Randen U, Oksman M, et al. Bendamustine plus rituximab for chronic cold agglutinin disease: results of a Nordic prospective multicenter trial. Blood. 2017;130(4):537–541.
   PubMed Web of Science ®Google Scholar
• Michel M, Terriou L, Roudot-Thoraval F, et al. A randomized and double-blind controlled trial evaluating the safety and efficacy of rituximab for warm auto-immune hemolytic anemia in adults (the RAIHA study). Am J Hematol. 2017;92(1):23–27.
   PubMed Web of Science ®Google Scholar
• Salama A. Treatment options for primary autoimmune hemolytic anemia: a short comprehensive review. Transfus Med Hemother. 2015;42(5):294–301.
   PubMed Web of Science ®Google Scholar
• Cheung WW, Hwang GY, Tse E, et al. Alemtuzumab induced complete remission of autoimmune hemolytic anemia refractory to corticosteroids, splenectomy and rituximab. Haematologica. 2006;91(5 Suppl):ECR13.
   PubMedGoogle Scholar
• Dasanu CA. Bortezomib: friend or foe of hemolytic anemia? J Oncol Pharm Pract. 2011;17(3):233–235.
   PubMedGoogle Scholar
• Tolbert VP, Goldsby R, Huang J, et al. Daratumumab is effective in the treatment of refractory post-transplant autoimmune hemolytic anemia: a pediatric case report. Blood. 2016;128:4819.
   Google Scholar
• Shi J, Rose EL, Singh A, et al. TNT003, an inhibitor of the serine protease C1s, prevents complement activation induced by cold agglutinins. Blood. 2014;123(26):4015–4022.
   PubMed Web of Science ®Google Scholar
• Tan SL, Liao C, Lucas MC, et al. Targeting the SYK-BTK axis for the treatment of immunological and hematological disorders: recent progress and therapeutic perspectives. Pharmacol Ther. 2013;138(2):294–309.
   PubMed Web of Science ®Google Scholar
• Wang Y, Tian Z, Thirumalai D, et al. Neonatal Fc receptor (FcRn): a novel target for therapeutic antibodies and antibody engineering. J Drug Target. 2014;22(4):269–278.
   PubMed Web of Science ®Google Scholar
• Allhorn M, Briceño JG, Baudino L, et al. The IgG-specific endoglycosidase EndoS inhibits both cellular and complement-mediated autoimmune hemolysis. Blood. 2010;115(24):5080–5088.
   PubMed Web of Science ®Google Scholar
• Garvey B. Rituximab in the treatment of autoimmune haematological disorders. Br J Haematol. 2008;141(2):149–169.
   PubMed Web of Science ®Google Scholar
• Barcellini W, Zanella A. Rituximab therapy for autoimmune haematological diseases. Eur J Intern Med. 2011;22(3):220–229.
   PubMed Web of Science ®Google Scholar
• Peñalver FJ, Alvarez-Larrán A, Díez-Martin JL, et al. Rituximab is an effective and safe therapeutic alternative in adults with refractory and severe autoimmune hemolytic anemia. Ann Hematol. 2010;89:1073–1080.
   PubMed Web of Science ®Google Scholar
• D’Arena G, Laurenti L, Capalbo S, et al. Rituximab therapy for chronic lymphocytic leukemia-associated autoimmune hemolytic anemia. Am J Hematol. 2006;81:598–602.
   PubMed Web of Science ®Google Scholar
• Zecca M, Nobili B, Ramenghi U, et al. Rituximab for the treatment of refractory autoimmune hemolytic anemia in children. Blood. 2003;101(10):3857–3861.
   PubMed Web of Science ®Google Scholar
• Fu R, Yan S, Wang X, et al. A monocentric retrospective study comparing pulse cyclophosphamide therapy versus low dose rituximab in the treatment of refractory autoimmune hemolytic anemia in adults. Int J Hematol. 2016;104(4):462–467.
   PubMed Web of Science ®Google Scholar
• Zaja F, Vianelli N, Sperotto A, et al. Anti-CD20 therapy for chronic lymphocytic leukemia-associated autoimmune diseases. Leuk Lymphoma. 2003;44:1951–1955.
   PubMed Web of Science ®Google Scholar
• Maung SW, Leahy M, O’Leary HM, et al. A multi-center retrospective study of rituximab use in the treatment of relapsed or resistant warm hemolytic anemia. Br J Haematol. 2013;163:118–122.
   PubMed Web of Science ®Google Scholar
• Laribi K, Bolle D, Ghnaya H, et al. Rituximab is an effective and safe treatment of relapse in elderly patients with resistant warm AIHA. Ann Hematol. 2016;95(5):765–769.
   PubMed Web of Science ®Google Scholar
• Berentsen S, Ulvestad E, Langholm R, et al. Primary chronic cold agglutinin disease: a population based clinical study of 86 patients. Haematologica. 2006;91(4):460–466.
   PubMed Web of Science ®Google Scholar
• Bocian H, Piatek C, Liebman HA, et al. Combination treatment of rituximab, cyclophosphamide, and dexamethasone for warm autoimmune hemolytic anemia. Blood. 2016;128:4802.
   Google Scholar
• Mariette X, Rouanet S, Sibilia J, et al. Evaluation of low-dose rituximab for the retreatment of patients with active rheumatoid arthritis: a non-inferiority randomised controlled trial. Ann Rheum Dis. 2014;73:1508–1514.
   PubMed Web of Science ®Google Scholar
• Vazquez-Mellado A, Pequeño-Luévano M, Cantu-Rodriguez OG, et al. More about low-dose rituximab and plasma exchange as front-line therapy for patients with thrombotic thrombocytopenic purpura. Hematology. 2016;21:311–316.
   PubMed Web of Science ®Google Scholar
• Visentini M, Tinelli C, Colantuono S, et al. Efficacy of low-dose rituximab for the treatment of mixed cryoglobulinemia vasculitis: phase II clinical trial and systematic review. Autoimmun Rev. 2015;14:889–896.
   PubMed Web of Science ®Google Scholar
• Zaja F, Vianelli N, Volpetti S, et al. Low-dose rituximab in adult patients with primary immune thrombocytopenia. Eur J Haematol. 2010;85(4):329–334.
   PubMed Web of Science ®Google Scholar
• Li Z, Mou W, Lu G, et al. Low-dose rituximab combined with short-term glucocorticoids up-regulates Treg cell levels in patients with immune thrombocytopenia. Int J Hematol. 2011;93(1):91–98.
   PubMed Web of Science ®Google Scholar
• Barcellini W, Zaja F, Zaninoni A, et al. Sustained response to low-dose rituximab in idiopathic autoimmune hemolytic anemia. Eur J Haematol. 2013;91(6):546–551.
   PubMed Web of Science ®Google Scholar
• Lachowiez C, Deodhar AKozin E. Obinutuzumab is effective in chronic lymphocytic leukemia and rheumatoid arthritis after rituximab failure: a case report. Am J Case Rep. 2017;18:516–519.
   PubMed Web of Science ®Google Scholar
• Nader KPatel M, Ferber a. Ofatumumab In Rituximab-refractory Autoimmune Hemolytic Anemia Associated With Chronic Lymphocytic Leukemia: A Case Report And Review Of Literature. Clin Lymphoma Myeloma Leuk. 2013;13(4):511–3.
   Google Scholar
• Davies A, Merli F, Mihaljevic B, et al. Safety of subcutaneous rituximab in follicular lymphoma (SABRINA): stage 1 analysis of a randomised phase 3 study. Lancet Oncol. 2014;15(3):343–352.
   PubMed Web of Science ®Google Scholar
• Assouline S, Buccheri V, Delmer A, et al. Pharmacokinetics, safety, and efficacy of subcutaneous versus intravenous rituximab plus chemotherapy as treatment for chronic lymphocytic leukaemia (SAWYER): a phase 1b, open-label, randomised controlled non-inferiority trial. Lancet Haematol. 2016;3(3):e128–38.
   PubMed Web of Science ®Google Scholar
• Wolfromm A, Mittaine B, Gandrille N, et al. Home administration of subcutaneous rituximab is safe and associated with significant cost saving: a single center experience. 59th annual meeting of the American Society of Hematology; 2017 Dec 9–12; Atlanta (GA).
   Google Scholar
• Iuliano F, Iuliano E, Perricelli A, et al. Rituximab subcutaneous formulation (SC-R) is safe, effective and cost-saving in patients suffering from Autoimmune Hemolytic Anemia (AIHA). 58th annual meeting of the American Society of Hematology; 2016 Dec 3–6; San Diego (CA).
   Google Scholar
• Allison AC, Eugui EM. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology. 2000;47(2–3):85–118.
   PubMed Web of Science ®Google Scholar
• Miano M, Ramenghi U, Russo G. Mycophenolate mofetil for the treatment of children with immune thrombocytopenia and Evans syndrome. A retrospective data review from the Italian Association of Paediatric Haematology/Oncology. Br J Haematol. 2016;175(3):490–495.
   PubMed Web of Science ®Google Scholar
• Howard J, Hoffbrand AV, Prentice HG, et al. Mycophenolate mofetil for the treatment of refractory auto-immune haemolytic anaemia and auto-immune thrombocytopenia purpura. Mehta A. Br J Haematol. 2002;117(3):712–715.
   PubMed Web of Science ®Google Scholar
• Kotb R, Pinganaud C, Trichet C, et al. Efficacy of mycophenolate mofetil in adult refractory auto-immune cytopenias: a single center preliminary study. Eur J Haematol. 2005 Jul;75(1):60–64.
   PubMed Web of Science ®Google Scholar
• Khandelwal P, Davies SM, Grimley MS, et al. Bortezomib for refractory autoimmunity in pediatrics. Biol Blood Marrow Transplant. 2014;20(10):1654–1659.
   PubMedGoogle Scholar
• Mehta B, Mahadeo K, Zaw R, et al. Bortezomib for effective treatment of a child with refractory autoimmune hemolytic anemia post allogeneic hematopoietic stem cell transplant. Pediatr Blood Cancer. 2014;61(12):2324–2325.
   PubMed Web of Science ®Google Scholar
• Hosoba S, Jaye DL, Cohen C, et al. Successful treatment of severe immune hemolytic anemia after allogeneic stem cell transplantation with bortezomib: report of a case and review of literature. Transfusion. 2015;55(2):259–264.
   PubMed Web of Science ®Google Scholar
• Carson KR, Beckwith LG, Mehta J. Successful treatment of IgM-mediated autoimmune hemolytic anemia with bortezomib. Blood. 2010;115(4):915.
   PubMed Web of Science ®Google Scholar
• Danchaivijitr P, Yared J, Rapoport AP. Successful treatment of IgG and complement-mediated autoimmune hemolytic anemia with bortezomib and low-dose cyclophosphamide. Am J Hematol. 2011;86(3):331–332.
   PubMed Web of Science ®Google Scholar
• Rossi G, Paoloni F, Fattizzo B Short course of bortezomib in anemic patients with refractory or relapsed cold agglutinin disease. a phase II prospective study by the Gimema group. 59th annual meeting of the American Society of Hematology; 2017 Dec 9–12; Atlanta (GA).
   Google Scholar
• Wouters D, Zeerleder S. Complement inhibitors to treat IgM-mediated autoimmune hemolysis. Haematologica. 2015;100(11):1388–1395.
   PubMed Web of Science ®Google Scholar
• Parker CJ, Kar S, Kirkpatrick P. Eculizumab. Nat Rev Drug Discov. 2007;6(7):515–516.
   PubMed Web of Science ®Google Scholar
• Röth A, Bommer M, Hüttmann A, Complement inhibition with eculizumab in patients with Cold Agglutinin Disease (CAD): results from a prospective phase II trial (DECADE Trial). 57th Annual Meeting of the American Society of Hematology; 2015 Dec 3–6. Orlando (FL).
   Google Scholar
• Gupta N, Wang ES. Long-term response of refractory primary cold agglutinin disease to eculizumab therapy. Ann Hematol. 2014;93(2):343–344.
   PubMed Web of Science ®Google Scholar
• Hill A, Rother RP, Arnold L, et al. Eculizumab prevents intravascular hemolysis in patients with paroxysmal nocturnal hemoglobinuria and unmasks low-level extravascular hemolysis occurring through C3 opsonization. Haematologica. 2010;95(4):567–573.
   PubMed Web of Science ®Google Scholar
• Lindorfer MA, Pawluczkowycz AW, Peek EM, et al. A novel approach to preventing the hemolysis of paroxysmal nocturnal hemoglobinuria: both complement-mediated cytolysis and C3 deposition are blocked by a monoclonal antibody specific for the alternative pathway of complement. Blood. 2010;115(11):2283–2291.
   PubMed Web of Science ®Google Scholar
• Risitano AM, Notaro R, Pascariello C, et al. The complement receptor 2/factor H fusion protein TT30 protects paroxysmal nocturnal hemoglobinuria erythrocytes from complement-mediated hemolysis and C3 fragment. Blood. 2012;119(26):6307–6316.
   PubMed Web of Science ®Google Scholar
• Hebecker M, Alba-Dominguez M, Roumenina LT, et al. An engineered construct combining complement regulatory and surface-recognition domains represents a minimal-size functional factor H. J Immunol. 2013;191(2):912–921.
   PubMed Web of Science ®Google Scholar
• Zimmerman JL, Dellinger RP, Straube RC, et al. Phase I trial of the recombinant soluble complement receptor 1 in acute lung injury and acute respiratory distress syndrome. Crit Care Med. 2000;28(9):3149–3154.
   PubMed Web of Science ®Google Scholar
• Risitano AM, Ricklin D, Huang Y, et al. Peptide inhibitors of C3 activation as a novel strategy of complement inhibition for the treatment of paroxysmal nocturnal hemoglobinuria. Blood. 2014;123(13):2094–2101.
   PubMed Web of Science ®Google Scholar
• Grossi FV, Bedwell P, Deschatelets P, et al. APL-2, a complement C3 inhibitor for the potential treatment of paroxysmal nocturnal hemoglobinuria (PNH): phase I data from two completed studies in healthy volunteers. 58th annual meeting of the American Society of Hematology; 2016 Dec 3–6; San Diego (CA).
   Google Scholar
• Clinicaltrials.gov [internet]. Study to assess the safety, tolerability, efficacy and PK of APL-2 in patients with wAIHA or CAD. Available from: https://clinicaltrials.gov/ct2/show/NCT03226678.
   Google Scholar
• Wouters D, Stephan F, Strengers P, et al. C1-esterase inhibitor concentrate rescues erythrocytes from complement-mediated destruction in autoimmune hemolytic anemia. Blood. 2013;121(7):1242–1244.
   PubMed Web of Science ®Google Scholar
• Botto M, Walport MJ. C1q, autoimmunity and apoptosis. Immunobiology. 2002;205(4–5):395–406.
   PubMed Web of Science ®Google Scholar
• Jaeger U, D’Sa S, Schoergenhofer C, et al. Long term efficacy, safety and PK/PD profile of the anti-c1s antibody (BIVV009) in primary cold agglutinin disease patients. 59th annual meeting of the American Society of Hematology; 2017 Dec 9–12; Atlanta (GA).
   Google Scholar
• Rogers KA, Ruppert AS, Bingman A, et al. Incidence and description of autoimmune cytopenias during treatment with ibrutinib for chronic lymphocytic leukemia. Leukemia. 2016;30(2):346–350.
   PubMed Web of Science ®Google Scholar
• Rogers KA, Lehman AM, Cheney C, et al. Inhibitors of Bruton’s tyrosine kinase reduce anti-red blood cell response in a murine model of autoimmune hemolytic anemia. 58th annual meeting of the American Society of Hematology; 2016 Dec 3–6; San Diego (CA).
   Google Scholar
• Cavazzini F, Lista E, Quaglia FM, et al. Response to ibrutinib of refractory life-threatening autoimmune hemolytic anemia occurring in a relapsed chronic lymphocytic leukemia patient with 17p deletion. Leuk Lymphoma. 2016;57(11):2685–2688.
   PubMed Web of Science ®Google Scholar
• Manda S, Dunbar N, Marx-Wood CR, et al. Ibrutinib is an effective treatment of autoimmune haemolytic anaemia in chronic lymphocytic leukaemia. Br J Haematol. 2015;170(5):734–736.
   PubMed Web of Science ®Google Scholar
• Hampel PJ, Larson MC, Kabat B, et al. Autoimmune cytopenias in patients with chronic lymphocytic leukemia treated with ibrutinib. 59th annual meeting of the American Society of Hematology; 2017 Dec 9–12; Atlanta (GA).
   Google Scholar
• Tsang M, Parikh SA. A concise review of autoimmune cytopenias in chronic lymphocytic leukemia. Curr Hematol Malig Rep. 2017;12(1):29–38.
   PubMed Web of Science ®Google Scholar
• Newland A, Lee EJ, McDonald V, et al. Fostamatinib for persRstent/chronic adult immune thrombocytopenia. Immunotherapy. 2018;10(1):9–25.
   PubMed Web of Science ®Google Scholar
• Clinicaltrials.gov [internet]. Phase 2, multi-center, open label, Simon two-stage study to evaluate the safety and efficacy of fostamatinib disodium in the treatment of warm antibody. Available from: https://clinicaltrials.gov/ct2/show/NCT02612558.
   Google Scholar
• Blumberg L, Humphries JE, Lasseter KC, et al. SYNT001: a humanized IgG4 monoclonal antibody that disrupts the interaction of FcRn and IgG for the treatment of IgG-mediated autoimmune diseases. 59th annual meeting of the American Society of Hematology; 2017 Dec 9–12; Atlanta (GA).
   Google Scholar
• Clinicaltrials.gov [internet]. A phase 1b, multicenter, open-label, safety, tolerability, and activity study of SYNT001 in subjects with chronic, stable warm autoimmune hemolytic anemia (WAIHA). Available from: https://clinicaltrials.gov/ct2/show/NCT03075878.
   Google Scholar
• Calkins CE. Regulatory T cells essential to prevent the loss of self-tolerance in murine models of erythrocyte-specific autoantibody responses. Immunol Res. 2011;51(2–3):134–144.
   PubMed Web of Science ®Google Scholar
• Wong ASL, Richards AL, Hudson KE Tolerization of CD4+ recent thymic emigrants is required to prevent RBC-specific autoimmunity. 59th annual meeting of the American Society of Hematology; 2017 Dec 9–12; Atlanta, GA.
   Google Scholar
• Zhou QN, Xing LM, Fu R, et al. Count and function of CD8(+)CXCR3(+) regulatory T cells in peripheral blood of patients with autoimmune hemolytic anemia. Zhonghua Yi Xue Za Zhi. 2011 28;91(24):1687–1690.
   PubMedGoogle Scholar
• Ahmad E, Elgohary T, Ibrahim H. Naturally occurring regulatory T cells and interleukins 10 and 12 in the pathogenesis of idiopathic warm autoimmune hemolytic anemia. J Investig Allergol Clin Immunol. 2011;21(4):297–304.
   PubMed Web of Science ®Google Scholar
• Fattizzo B, Zaninoni A, Gianelli U, et al. Prognostic impact of bone marrow fibrosis and dyserythropoiesis in autoimmune hemolytic anemia. Am J Hematol. [Epub ahead of print] Dec 23 2017. DOI10.1002/ajh.25020
   Web of Science ®Google Scholar
• Osterborg A, Karlsson C, Lundin J. Alemtuzumab to treat refractory autoimmune hemolytic anemia or thrombocytopenia in chronic lymphocytic leukemia. Curr Hematol Malig Rep. 2009;4(1):47–53.
   PubMedGoogle Scholar
• Lauro A, Stanzani M, Finelli C, et al. Alemtuzumab plus cyclosporine treatment of the autoimmune hemolytic anemia in an adult bowel transplant. Case Rep Transplant. 2014;2014:262953.
   PubMedGoogle Scholar
• Osterborg AKarlsson C, Lundin j. Alemtuzumab To Treat Refractory Autoimmune Hemolytic Anemia Or Thrombocytopenia In Chronic Lymphocytic Leukemia. Curr Hematol Malig Rep. 2009;4(1):47–53.
   Google Scholar
• Rogers KA, Lehman AMCheney C. Inhibitors of bruton's tyrosine kinase reduce anti-red blood cell response in a murine model of autoimmune hemolytic anemia. Blood. San Diego 58th Ash Meeting 2016. 2016;128:1259.
   Google Scholar
• Park JA, Lee HH, Kwon HS, et al. Sirolimus for refractory autoimmune hemolytic anemia after allogeneic hematopoietic stem cell transplantation: a case report and literature review of the treatment of post-transplant autoimmune hemolytic anemia. Transfus Med Rev. 2016;30(1):6–14.
   PubMed Web of Science ®Google Scholar
• Jasinski S, Weinblatt ME, Glasser CL. Sirolimus as an effective agent in the treatment of Immune Thrombocytopenia (ITP) and Evans Syndrome (ES): a single institution’s experience. J Pediatr Hematol Oncol. 2017;39(6):420–424.
   PubMed Web of Science ®Google Scholar
• Clinicaltrials.gov [internet]. Evaluating the interest of interleukine-2 for patients with active warm hemolytic anemia resistant to conventional treatment (ANEMIL). Available from: https://clinicaltrials.gov/ct2/show/NCT02389231.
   Google Scholar
• Miklos D, Cutler CS, Arora M, et al. Ibrutinib for chronic graft-versus-host disease after failure of prior therapy. Blood. 2017
   Google Scholar
• Mahévas M, Michel M, Vingert B, et al. Emergence of long-lived autoreactive plasma cells in the spleen of primary warm auto-immune hemolytic anemia patients treated with rituximab. J Autoimmun. 2015;62:22–30.
   PubMed Web of Science ®Google Scholar
• Gudbrandsdottir S, Frederiksen H, Hasselbalch H. Thrombopoietin-receptor agonists in haematological disorders: the Danish experience. Platelets. 2012;23(6):423–429.
   PubMed Web of Science ®Google Scholar
• Barcellini W, Fattizzo B, Zaninoni A. Clinical evolution of autoimmune cytopenias to idiopathic cytopenias/dysplasias of uncertain significance (ICUS/IDUS) and bone marrow failure syndromes. Am J Hematol. 2017;92(3):E26–E29.
   PubMed Web of Science ®Google Scholar